Understanding genetic risks in acute myeloid leukemia based on ancestry
Official title: Towards an inclusive genomic risk classification for acute myeloid leukemia (AML)
Funded at Ohio State University · NIH-10930899 · Data updated 2026-11-12
This study is looking at how your genetic background might affect your risk of getting acute myeloid leukemia and how well different treatments work for you, so we can better understand and help everyone, no matter their ancestry.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project start | September 18, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $622,018 |
| NIH project number | 5R01CA284595-02 |
| Project ID | NIH-10930899 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with acute myeloid leukemia, particularly those from diverse ancestral backgrounds.
✕Less likely to help
Patients with other types of leukemia or those who do not have a genetic component to their AML may not benefit from this research.
What this research studies
This research investigates how genetic factors related to ancestry influence the risk and treatment outcomes for acute myeloid leukemia (AML). By analyzing genomic data from diverse populations, the study aims to identify specific genetic mutations that may affect prognosis and treatment responses differently based on a patient's ancestry. The approach includes extensive genomic analysis and statistical modeling to refine risk classifications for AML, ensuring they are inclusive and representative of all populations. Patients may be involved in providing genetic samples and clinical data to support this important work.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective treatment strategies for AML patients based on their genetic background.
How similar studies have gone: Previous research has shown that ancestry can significantly impact genetic risk factors in various cancers, suggesting that this approach may yield valuable insights for AML as well.
Where this research is happening
-
Ohio State University
Columbus, United States Active
Researchers
- Principal investigator: Eisfeld, Ann-Kathrin — Ohio State University
- Study coordinator: Eisfeld, Ann-Kathrin
Related research
Other NIH-funded projects on the same topics.
-
Acute Myeloid Leukemia: Improving Targeted Therapies through Genetically Defined PDX Models
Researchers are using patient-like leukemia models to develop therapies that target specific genetic features of AML to improve survival.
-
A broader genomic risk picture to guide AML treatment
AIM to refine how genetic information guides treatment decisions for adults with acute myeloid leukemia by looking at how inherited and recurrent mutations affect risk.
-
RNA Polymerase II as a Therapeutic Target in AML with RAS Activation
This project explores a new way to treat a common type of blood cancer (AML) by blocking a key machinery (RNA Polymerase II) that cancer cells use when the RAS signaling pathway is overactive.
-
SHP2 and BCL2 inhibitors together for AML growth and resistance
A patient-focused look at whether combining SHP2 inhibitors with a BCL2 inhibitor can slow or stop AML, especially in people whose disease has FLT3 or KIT mutations.
-
Targeting RNA polymerase II in AML with RAS pathway activation
This project tests drugs that block RNA polymerase II to help people whose acute myeloid leukemia has RAS pathway activation and is resistant to FLT3 inhibitors.
-
New treatment approach for myelodysplastic syndrome and acute myeloid leukemia
This project aims to develop a new antibody-based therapy to help people with MDS or AML, especially older or frail patients who cannot tolerate high-dose chemotherapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.